The Rahway company continues to invest in its 2030s future, here getting a first look at Infinimmune’s high value antibody targets for various diseases (both viral and cancerous) — to become candidates for therapies or vaccines.
Here’s the latest, from Fierce Biotech:
…Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million.
The New Jersey pharma is tapping Infinimmune to hunt for antibodies for as-of-yet undisclosed targets. The $838 million total comes from an undisclosed upfront payment and future potential milestone payouts, according to a March 31 release. Once Infinimmune identifies a potential antibody under the deal, Merck will have the exclusive right to take over development and commercialization.
Infinimmune’s platform uses a large dataset sourced from human memory B cells, which the company believes makes its antibody candidates already primed to become new drugs….
Onward, grinning….
नमस्ते
Powerline Lies... 